Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

Sekine, Ikuo; Nokihara, Hiroshi; Horiike, A.; Yamamoto, Noboru; Kunitoh, Hideo; Ohe, Yuichiro; Tamura, Tomohide; Kodama, T; Saijo, N.

doi:10.1038/sj.bjc.6601700

Cited by 14 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Naito [ 5 ] investigated efficacy of a nedaplatin and docetaxel regimen in advanced squamous cell lung carcinoma. The doublet produced an objective response rate of 62% and an overall survival of 16.1 months, which was comparable to the results in earlier studies [ 6 , 7 ]. But although attention has been paid to the efficacy of nedaplatin and its comparison to cisplatin, few studies have focused on its histological specificity.…”

Section: Introductionsupporting

confidence: 88%

Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers

Tian

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) consists of several subtypes, including adenocarcinoma, squamous cell lung cancer, large cell lung cancer, and other rarer types. Platinum-based regimens are currently the standard for treatment of advanced NSCLC. Nedaplatin is reportedly associated with a high response rate in squamous cell lung cancer. However, the relevant studies are small and mainly descriptive. The purpose of this meta-analysis was therefore to compare the efficacy of nedaplatin in squamous cell lung cancer with that in non-squamous cell lung cancer. Studies concerning nedaplatin-based regimens in NSCLC patients were retrieved from PubMed and EMBASE. The response rate for nedaplatin-based regimens in squamous cell lung cancer (ORR: 55.6%, 95% CI: 52.5-58.7%) was higher (OR: 1.55, 95% CI: 1.17-2.05) than that for non-squamous cell lung cancer (ORR: 34.4%, 95% CI: 32.3-36.5%). In addition, Taxane plus nedaplatin produced a longer overall and progress-free survival than CPT-11 or gemcitabine plus nedaplatin. To verify these findings, future well-controlled clinical studies will be needed.

show abstract

Section: Introductionsupporting

confidence: 88%

Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers

Tian

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…The antineoplastic activity of nedaplatin, a cisplatin derivate developed in 1983 [ 43 ], might be mediated by mechanisms distinct from those of p53-dependent early apoptosis [ 44 ]. Several studies have demonstrated that a nedaplatin-based treatment regimen [ 45 – 47 ] for squamous cell lung cancer is superior to a cisplatin or carboplatin-based regimen [ 48 ]. Our work provides a potential rationale for nedaplatin as the optimal choice for NSCLC patients with KEAP1 mutations.…”

Section: Discussionmentioning

confidence: 99%

Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer

Tian

Liu

et al. 2016

J Hematol Oncol

View full text Add to dashboard Cite

BackgroundThe objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-associated protein 1 (KEAP1) mutations and to determine the role of NRF2 and KEAP1 on platinum-based drug treatment.MethodsWe used real-time PCR to assess relative mRNA expression and used western blotting and immunofluorescence assays to assess protein expression. Small interfering RNA and shuttle plasmids were used to modulate the expression of NRF2, wild-type KEAP1, and mutant KEAP1. Drug sensitivity to platinum-based drugs was evaluated with Cell Count Kit-8.ResultsWe found that platinum-based therapies modified the NRF2 signaling pathway differently in KEAP1-mutated non-small cell lung cancer (NSCLC) cell lines compared with wild-type KEAP1 cell lines. The reactive degree of NRF2 signaling also varies between nedaplatin and cisplatin. The modification of NRF2 or KEAP1 expression in NSCLC cell lines disrupted downstream gene expression and cell sensitivity to platinum-based drugs. Finally, gene expression data retrieved from The Cancer Genome Atlas (TCGA) consortium indicated that KEAP1 mutation significantly affects NRF2 signaling activity in patients with NSCLC.ConclusionsOur findings suggest that NRF2 signaling plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and provides a rationale for using NRF2 as a specific biomarker for predicting which patients will be most likely to benefit from platinum-based treatment.

show abstract

“…Although the phase I study of the combination of paclitaxel and nedaplatin for uterine cervical cancer has not been reported, Yoshiike et al reported the recommended dose of paclitaxel and nedaplatin were 180 mg/m 2 and 80 mg/m 2 , respectively which resulted from a phase I study for non-small cell lung cancer [12]. Sekine et al conducted a phase I study for un-resectable squamous cell carcinoma of lung and thymus, head and neck, and reported the recommended dose were 180 mg/m 2 of paclitaxel and 100 mg/m 2 of nedaplatin [13]. We considered that the results were reliable although the patients in these studies have not had prior pelvic radiation, so we initiated a phase II trial to evaluate the activity and toxicity of the combination of these two agents in 2007.…”

Section: Introductionmentioning

confidence: 96%

Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: A Kansai Clinical Oncology Group study

Takekuma

Hirashima

Ito

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

Cited by 14 publications

References 12 publications

Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers

Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers

Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer

Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: A Kansai Clinical Oncology Group study

Contact Info

Product

Resources

About